Uploaded byhughcarter
PDF, PPTX2,383 views

Aurora investor presentation - April 2018

The document provides an overview of Aurora Cannabis Inc., a company focused on the production and distribution of medical cannabis. Key points: - Aurora has over 280,000 kg per year of funded production capacity across several facilities. - The company pursues growth through innovation, execution, expansion internationally and through acquisitions. It has acquired 8 companies and made 7 strategic investments. - Aurora is well positioned for international growth, with existing sales or operations in Germany, Denmark, Italy, Australia, Cayman Islands, and South Africa. It aims to capitalize on medical cannabis markets in Europe and globally.

Embed presentation

Download as PDF, PPTX
A PR IL 2018 AGILITY INNOVATION EXECUTION AND EXPANSION Talented, experienced management team driving the sector's fastest growth in customers, revenues and shareholder value
Forward Looking Statements This Presentation (the “Document”) by Aurora Cannabis Inc. (“Aurora” or the “Company”) has been compiled by management of the Company solely for information purposes. The Document has been prepared and dated as of March 31, 2017, and the information contained herein is current as of such date only. The Document under no circumstances is to be construed to be an offering of securities. Neither this Document, nor its delivery to the recipient shall constitute an offer to sell, or the solicitation of an offer to buy the assets described herein. It is provided solely for use by prospective investors in considering their interest. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its business and does not purport to contain all the information that prospective investors may require. Prospective investors should conduct their own investigation and analysis of the Company and its business and the information contained in this Document as well as any additional information provided by the Company. This Document includes forward-looking statements within the meaning of certain securities laws, including the “safe harbour” provisions of the Securities Act (Ontario, Alberta and British Colombia) and other provincial securities law in Canada. These forward- looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward- looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. The Company strongly cautions readers not to place undue reliance on these statements, as a number of important factors, many of which are beyond our control, could cause the Company’s actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to: general economic conditions; pending and proposed legislative or regulatory developments in Canada including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models in Canada; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total patients and customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; structural subordination of common shares; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and future sales of the Company’s securities. The foregoing list of important factors that may affect future results is not exhaustive. When reviewing the Company’s forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by Canadian securities law, the Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by the Company or on the Company’s behalf. Such statements speak only as of the date made. The forward-looking statements contained in this Document should not be relied upon as representing the view of the Company or its management as of any date subsequent to the date of this Document. Neither the Company nor its management is under any obligation, and neither undertakes, to update any of this information at any particular time. Neither the Company nor its management assumes any obligation to update or revise forward-looking statements should circumstances or estimates or opinions changes. None of the Company or its affiliated or related partnerships and corporations or their respective directors, officers, partners, employees, agents or representatives makes any representation or warranty as to the accuracy or completeness of the Document or any statements, estimates or projections, and none will assume any liability for any representations (express or implied) contained in, or for any omissions from, the Document, or for any other written or oral communications transmitted to prospective investors in the course of their evaluation of the Company and its business. An investor will only be entitled to rely on those representations and warranties contained in the definitive agreement or agreements which constitute the financing. This presentation can not be copied, reproduced or distributed in whole or in part to others, at any time, without the prior express written consent of the Company. To the extent that they are included in this document, certain financial metrics can be reported as non-IFRS measures, such as EBITDA (earnings before interest, taxes, depreciation and amortization). For the purposes of this Document, EBITDA is calculated as revenue less cost of sales and operating expenses. The Company believes that these non-IFRS measures are appropriate measures of the operating performance of the Company. The Company’s calculation of these measures may differ from the methodology used by other issuers and, accordingly, may not be comparable to such other issuers. The Company believes that these measures are appropriate measures of the Company’s operating performance because they facilitate an understanding of operating performance without giving effect to certain non-cash and overhead expenses. None of these measures are equivalent to net income or cash flow from operating activities determined in accordance with IFRS. Aurora Cannabis Inc. Management Presentation 2
Highlights 1. Over 280,000 kg per year funded capacity 2. High-technology, ultra-efficient, low cost facilities 3. Strong revenue growth: last reported quarter (Q2 2018): 200% YoY and 41.8% QoQ 4. New production coming online, driving further growth 5. Continuously falling costs of production 6. Corporate expansion: 8 acquisitions and 7 strategic investments in past two years 7. Vertically integrated, horizontally diversified 8. Early mover advantage through rapidly growing international footprint • Own EU’s largest distributor of cannabis • Targeting international markets with nearly 800 million people and strong barriers to entry • Already have presence/sales/agreements in Canada, Germany, Denmark, Italy, Australia, Cayman Islands, South Africa Driven by agility, innovation and execution Aurora Cannabis Inc. Management Presentation 4
EXCEPTIONALLY WELL POSITIONED TO CAPITALIZE ON THE GLOBAL CANNABIS OPPORTUNITY 1VIII Capital, Cannabis Sector, July 2017 CANADA $12 B1 EU $37 B1 ROW $110 B1 PROJECTED MARKET POTENTIAL AGILITY INNOVATION EXECUTION EXPANSION
Agility • Fastest ramp up, execution and sales growth achieved relative to other LP’s • Focused strategy aimed at capitalizing on vertical and horizontal integration opportunities internationally and domestically • High pace of execution ensures early mover advantage and rapid capitalization on opportunities Aurora Cannabis Inc. Management Presentation 6 Source: SEDAR filings Fastest Growing LP’s – Sales License to 650kg/quarter 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 50,000 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18
Aurora Cannabis Inc. Management Presentation 7 AURORA LARSSEN PROJECTS • World’s premier greenhouse design consultancy AURORA SKY • World’s largest capacity and most technologically advanced cannabis cultivation facility • Optimized for highest yield and lowest cost per gram produced AURORA MOUNTAIN • World’s first fully purpose-built indoor cannabis facility, EU GMP certified CUSTOMER EXPERIENCE • The Aurora Standard: leading edge customer care • Only LP with mobile app for purchasing medical cannabis • Same-day delivery in Calgary, Edmonton and surrounding areas • e-Commerce • Product differentiation RADIENT TECHNOLOGIES – disruptive extraction technology for cannabis oil production NAMASTEMD - exclusive white label use for patient education and registration portal MICRON WASTE TECHNOLOGIES (6.5% interest) – low-cost environmentally friendly treatment of organic waste CANNAROYALTY – acquiring IP for portfolio of novel drug delivery technologies Establishing a world-leading brand, scale and efficiencies Innovation Across all Operational Areas CUSTOMER EXPERIENCE PRODUCTION INNOVAITON- DRIVEN PARTNERSHIPS
8 GLOBAL EXPANSION VERTICAL INTEGRATION DOMESTIC EXPANSION HORIZONTAL DIVERSIFICATION CAPITALIZATION STRATEGY AND EXECUTION 280,000 kg per annum funded capacity Strong balance sheet Direct and indirect presence on 3 continents 200% YoY revenue growth 8 Acquisitions 7 Strategic investments Multiple Strategic partnerships
Domestic Capacity Expansion 9 FACILITIES MOUNTAIN SKY VIE LACHUTE Footprint (square footage) 55,000 800,000 40,000 48,000 Status Operational since 2015 Licensed in January 2018 Completion by mid- 2018 Completed and Licensed Nov 2017 Completion early calendar 2018 Capacity 4,800 kg/yr 100,000+ kg/yr 4,000+ kg/yr 4,500+ kg/yr Key features First purpose built cannabis facility EU GMP certified Highly automated, technologically advanced cannabis facility for optimized yield and low cost production built to EU GMP standards. Located at Edmonton international airport for superior domestic and global logistics Technologi cally advanced, specialty strains for premium products and medical research Completed to EU GMP standards Nearly completed, state-of-the art facility to be completed to EU GMP standards 1 VIII Capital, Cannabis Sector, July 2017 TGOD Relationship 17.62% ownership interest Supply agreement for up to 23,200 kgpa Status BuIlding Larssen-designed 102,000 kgpa facility in Quebc Completing 14,000 kgpa facility in Ontario Funded Capacity 116,000+ kg/yr Key features Premium organic cannabis producer CANNIMED 97,000 Working on GMP certification Commenced expansion 19,000 kg/yr Current 7,000 kgéyr capacity to be expanded to 19,000 kg per year
Adding 19,000 kg per annum funded capacity Adding over 20,000 patients Expands international footprint CanniMed Acquisition Aurora Cannabis Inc. Management Presentation 10 To form core of Aurora’s Medical Cannabis Centre of Excellence Adds drug delivery technologies Strong Brands Well Connected Major Expansion Cannabis Oils • Significant sales acceleration since launching oils in 2016 • Phase 1 expansion - $1 billion revenue capacity with 70+% profit margins • 12 million bottles / year @ 165.00 per 60 ml • Completed first oils export to Australia and Cayman Islands • Extraordinary capability and expertise Capsules Production • Expected to accelerate growth in Canada and internationally • For baby boomers looking for a safe, reliable way to manage their chronic pain symptoms and maintain an active lifestyle Topical Cream • Recently launched leading trans-dermal topical cream
International Expansion Aurora Cannabis Inc. Management Presentation 11 ~588.8M = combined population Italy Sells cannabis to the Italian government through Pedanios Denmark Owns 51% of Aurora Nordic where Europe’s largest cannabis facility is being built at 1,000,000 sq ft Germany Sells cannabis through Pedanios, leading wholesale importer/exporter/distributer Australia 22.9% interest in Cann Group, first Australian company licenced to cultivate medical cannabis South Africa Definitive agreement to supply cannabis products to Akula Trading 2 Pty Ltd. Cayman Islands First ever sale of commercial cannabis oils Australia First ever shipment of commercial cannabis oils European Union LOI with Creso Pharma Ltd. to market CMED medical cannabis brands Aurora CanniMed Both Aurora & CanniMed • Potentially very large markets • But with strong barriers to entry • Requires EU GMP certification to participate • Aurora is one of few companies with such certification • Accelerating international expansion through CanniMed transaction
• International medical market growing at a 21% CAGR until 2025 • Near to mid-term expansion through medical-focused opportunities • Multiple GMP-certified facilities to export to international markets Country Population (MM) Medical Cannabis? Name of Regulation Year Voted In Implied Demand (kg per year) Medical Market Sizes If flower Only ($MM) Flower + Extracts ($MM) Active Medical Cannabis Laws Argentina 43.4 ✓ - 2017 316,820 $2,218 $3,564 Austria 8.5 ✓ - 2008 62,050 $434 $698 Australia 23.9 ✓ Narcotics Drug Amendment Bill 2016 174,470 $1,221 $1,963 Canada 35.9 ✓ ACMPR 2001 262,070 $1834 $2,948 Chile 17.9 ✓ Decree 84 2015 130,670 $915 $1470 Columbia 48.2 ✓ - 2015 251,860 $2,463 $3,958 Croatia 4.2 ✓ - 2015 30,660 $215 $345 Czech Republic 10.5 ✓ Amendments 50/2013 Coll. & 221/2013 Coll. 2013 76,650 $537 $862 Germany 80.5 ✓ - 2017 589,110 $4,124 $6,627 Israel 8.1 ✓ - 1992 59,130 $414 $665 Italy 59.8 ✓ - 2007 436,540 $3,056 $4,911 Jamaica 2.8 ✓ Dangerous Drugs (Amendment) Act 2015 2015 20,440 $143 $230 Macedonia 2.1 ✓ - 2016 15,330 $107 $172 Mexico 127 ✓ - 2017 927,100 $6,490 $10,430 Netherlands 16.9 ✓ - 2003 123,370 $864 $1,388 Norway 5.2 ✓ - 2016 37,960 $266 $427 Puerto Rico 3.7 ✓ - 2015 27,010 $189 $304 Romania 19.5 ✓ - 2013 142,350 $996 $1,601 Slovenia 2.1 ✓ - 2014 15,330 $107 $172 Switzerland 8.3 ✓ Federal Act on Narcotics and Psychotropic Substances 2008 60,590 $424 $682 Turkey 78.7 ✓ Legal in 19 provinces 2016 574,510 $4,022 $6,463 Uruguay 3.4 ✓ - 2013 24,820 $174 $279 Subtotal 610.8 4,358,840 $31,212 $50,162 Pending Medical Cannabis Laws or Countries of Interest Belgium 11.3 - - 82,490 $577 $928 Brazil 207.8 - - 1,516,940 $10,619 $17,066 Denmark 5.7 - - 41,610 $291 $468 Finland 5.5 - - 40,150 $281 $452 France 64.4 - - 470,120 $3,291 $5,289 Iceland 0.3 - - 2,190 $15 $25 Ireland 4.7 - - 34,310 $240 $386 New Zealand 4.5 - - 32,850 $230 $370 Poland 38.6 - - 281,780 $1,972 $3,170 Portugal 10.4 - - 75,920 $531 $854 Slovakia 5.4 - - 39,420 $276 $443 South Africa 54.5 - - 397,850 $2,785 $4,476 Spain 46.1 - - 336,530 $2,356 $3,786 United Kingdom 64.7 - - 472,310 $3,306 $5,313 United States 321.8 Legal 29 states and D.C. - 2,349,140 $16,444 $26,428 Subtotal 845.7 6,173,610 $79,154 $127,212 $180B Medical Market Coming Online Over the Next 10-15 Years Eight Capital – 2018 Outlook: legalization will lead to Globalization
13 Pedanios – Aurora’s Gateway to the EU Cannabis Market 82 million population Germany >400 million population EU • Largest medical cannabis distributor in EU (100% owned) • EU GMP certified for import, release and distribution of cannabis • Currently servicing >2,000 pharmacies in Germany (exclusive suppliers of patients) • Access to single largest federally legalized medical cannabis market with population > 82 million • Broad insurance coverage for prescribed medical cannabis • Limited number of EU GMP certified international producers • In phase 2 of tender process for German cultivation license • Won first public tender to supply Italian system Cornerstone acquisition for European expansion strategy
14 Aurora Nordic – Europe’s Largest Facility at 1,000,000 Square Feet 82 million population Germany Nordic focus wth option to export to wider EU with > 400 M people • Aurora Nordic: 51/49 JV with Alfred Pedersen, one of Europe’s largest greenhouse growers of vegetables (>100,000 kg per day) • Licensed to produce as of Jan 1, 2018 • To construct ALPS-designed high- technology facility • At 1,000,000 sqft, this will be largest cannabis facility in Europe • Focused on Nordic countries and export to rest of EU through Pedanios • Built to EU GMP standards for export • Retrofitting existing greenhouse for 8,000 kgpa capacity while main facility is being constructed JV Partner Recognized as one of Denmark’s leading entrepreneurs
Aurora – Industry Leading International Strategic Partnerships CanniMed – Strong International Presence With Meaningful Distribution Partners • Over the last two years, Aurora has completed 15 acquisitions and strategic investments, including: o Pedanios – EU`s largest distributor of cannabis, based in Germany – EU GMP certified o LIQ – Strategic investment in Western Canada’s largest liquor retail chain. LIQ to convert existing retail outlets and establish new ones for the sale of cannabis for the adult consumer use market o Radient Technologies – Partnership for the high-throughput extraction of cannabinoids Vertical Integration – Horizontal Diversification 15 Akula Trading 2 Pty Ltd. • CanniMed has built strong partnerships that position it well for future growth: o Avaria – CanniMed entered into an agreement with Avaria Health & Beauty Corp for the distribution of topical medical cannabis products, product development, and clinical research o PharmaChoice – Entered into Canada’s first exclusive pharmacy distribution agreement for medical cannabis o Canadian Cancer Survivor Network – Partnered with Canadian Cancer Survivor Network for medical cannabis education
Adult Consumer Use Market – LIQ Partnership • Acquired 19.9% of issued and outstanding shares in Liquor Stores N.A. (“LIQ”), with option to increase ownership to 40% • LIQ will use proceeds to convert existing stores, as well as build new stores, into cannabis retail outlets • LIQ has strong presence in Western Canada with over 200 liquor stores • One of the dominant retail brands in Western Canada • Ensures LIQ and Aurora will be ready on Day One of the commencement of cannabis sales for the adult consumer market, once legalized • Leveraging LIQs deep expertise, capabilities and capacity in operating a network of retail outlets • Aurora to contribute branding, product knowledge and understanding of the cannabis culture and markets Aurora Cannabis Inc. Management Presentation 16
BC Northern Lights – Supporting the Home Grow Market • The gold-standard in indoor grow boxes • Only purpose-built growing appliance on the market • Odor-free operation, ideal for multi-unit dwellings • Lockable doors • Only growing appliance that offers CSA/UL safety approval • Produced using premium materials and components only • Medical grade powder coated aluminum to avoid any mold or mildew issues • 20-year track record • Exceptional customer care • Customized nutrient management plans • Unlimited toll-free technical support • Live streaming “Growinars” • BCNL customers can speak to experienced growers and technicians seven days a week Aurora Cannabis Inc. Management Presentation 17
FINANCIAL SECTION 18
Aurora Cannabis Inc. Management Presentation 19 Sequential Growth (%) 200% YoY growth for Q2 2018 457.1% 151.7% 26.5% 33.2% 14.7% 39.0% Strong Revenue Growth Revenue ($M) $0.00 $2.00 $4.00 $6.00 $8.00 $10.00 $12.00 $14.00 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 41.8%
Rapid Development Relative to Sector Aurora Cannabis Inc. Management Presentation 20 0 5 10 15 20 25 Dec-14 Mar-15 Jun-15 Sep-15 Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Mar-17 Jun-17 Sep-17 Dec-17 LPs Revenue Development ACB WEED APH LEAF CMED ACB+CMED Notes to chart: LPs have different reporting schedules. For comparison reasons, revenues have been assigned to the corresponding Aurora quarter.
Strong Execution Drives Fastest Revenue Development Aurora Cannabis Inc. Management Presentation 21 0 2 4 6 8 10 12 14 1Q 2Q 3Q 4Q 5Q 6Q 7Q 8Q ACB WEED APH Revenue development first 8 quarters from commencement of sales 0 5 10 15 20 25 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 ACB WEED APH LEAF CMED ACB+CMED Revenue development since ACB commenced sales
Aurora Cannabis Inc. Management Presentation 22 Continuously Improving Metrics Q2 2018 Q1 2018 Q4 2017 Q3 2017 Q2 2017 # # # # # Active registered patients (1) 23,000 19,280 16,400 13,110 12,200 Grams sold 1,161,809 889,965 755,059 653,008 538,045 Grams produced (2) 1,204,259 1,009,585 1,164,683 846,849 670,322 (In CDN $000’s unless otherwise noted) $ $ $ $ $ Average net selling price per gram 8.36 8.22 7.45 6.64 5.96 Cash cost of sales per gram 1.74 1.92 2.09 2.31 2.56 Cash cost to produce per gram 1.41 1.73 1.91 1.91 2.13 Cash and cash equivalents 350,841 127,915 159,796 111,116 55,846
Aurora Cannabis Inc. Management Presentation 23 Company invested in Shares bought Average price Current Value RoI #(million) $ (million) $ (million) % Cann Group 28.8 0.84 82.9 Radient Technologies 23.2 0.57 38.5 Hempco Food and Fiber 10.6 0.31 11.4 Micron Waste Technologies 4.4 0.34 2.1 TOTAL 135 >200% Value Creation Through Strategic Investments Exceptional investment track record Also completed $55 million investment into The Green Organic Dutchman (private)
HIGHLIGHTS 24 Fastest patient sign up rate in industry Scale to service both rapidly growing medical market and seize legalization opportunity Extremely well capitalized to pursue global expansion opportunity • Upon completion, six facilities • > 280,000 kg per annum funded production capacity • Technologically most advanced facilities => ultra low cost of production • CanniMed acquisition • Pedanios - Germany & EU • Cann Group – Australia • Aurora Nordic - Denmark SCALE • Disruptive extraction technology • First mobile app for ordering medical cannabis • Customer care: same day delivery in two metropolitan areas INNOVATION • Technology-driven cultivation philosophy to produce high-quality cannabis at ultra low cost • Diversifying product offering into adjacent markets, accessing additional revenue streams DIFFERENTIATION/DIVERSIFICAITON INTERNATIONAL EXPANSION
Company Information 25
Experienced Leadership Team Aurora Cannabis Inc. Management Presentation 26 Terry Booth CEO CEO of 6 successful companies 25 years experience in highly regulated industries Cam Battley Chief Corporate Officer Deep experience in pharma and cannabis sectors Board member Cannabis Canada Steve Dobler President Successful entrepreneur, member of many public companies’ board of directors. Responsible for raising substantial funds for Aurora Glen Ibbott CFO Strong senior financial executive with deep life sciences sector experience Neil Belot Chief Global Business Development Officer Former executive director of Cannabis Canada - Canada's trade association for Licensed Producers Allan Cleiren COO Experienced operational executive with nearly three decades leadership experience at private and public companies Darryl Vleeming Chief Information Officer over 20 years of experience in Senior IT leadership, project delivery, and IT strategic planning at publicly traded international corporations, with a specific focus on driving business value.
Board of Directors Aurora Cannabis Inc. Management Presentation 27 Steve Dobler President, Aurora Successful entrepreneur, member of many public companies’ board of directors. Responsible for raising substantial funds for Aurora Adam Szweras Partner, Fogler, Rubinoff LLP Experienced securities lawyer. Founder of a US developer of marijuana and hemp oil, and edible products. Michael Singer Chairman CFO, Clementia Pharmaceuticals Former CFO, Bedrocan Cannabis Corp. Terry Booth CEO, Aurora CEO of 6 successful companies 25 years experience in highly regulated industries Dr. Jason Dyck Professor, Department of Pediatrics and Director of Cardiovascular Research Centre, University of Alberta Diane Jang A business consultant, specializing in strategic planning for sustainable success, growth and profitability, with over 27 years of business experience in the Consumer Packaged Goods industry
28 AGILITY INNOVATION EXECUTION EXPANSION Talented, experienced management team driving the sector's fastest growth in customers, revenues and shareholder value
Aurora Information Established 2013 ~750 Employees 6 Directors Head Office 1500 -1199 West Hastings St. Vancouver, BC V6E 3T5 TSX: ACB OTCQX: ACBFF Aurora Cannabis Inc. Management Presentation 29
Capital Summary Market Cap - Basic $4.5 Billion Share Price - April 3, 2018 $8.07 Aurora Cannabis Inc. Management Presentation 30Strong balance sheet to fuel further growth April 3, 2018 TSX listed, ticker symbol ACB Securities Issued & Outstanding Shares* 561,061,244 Options 25,087,884 Warrants 8,615,348 Convertible debentures shares reserved for issuance 17,976,203 Fully Diluted 614,890,679
Contact Information Cam Battley Chief Corporate Officer +1 (905) 878-5525 cam@auroramj.com 31 Marc Lakmaaker, Director IR & Corporate Development +1 (647) 269-5523 Marc.lakmaaker@auroramj.com

More Related Content

PPTX
Aurora AGM Presentation
byAuroraCannabis
 
PDF
Aurora investor presentation acquisition of canni-med therapeutics
byMarc Lakmaaker
 
PDF
Aurora investor presentation - january 2018
byAuroraCannabis
 
PDF
Zenabis Corporate Presentation
byZenabisIR
 
PDF
Management Presentation
bySleepCountry
 
PDF
Aurora investor presentation - january 2018
byAuroraCannabis
 
PPTX
Aurora Investor presentation December 2017
byAuroraCannabis
 
PDF
05.08.17 med releaf-en-presentation-amended
bymedreleafinvestor
 
Aurora AGM Presentation
byAuroraCannabis
 
Aurora investor presentation acquisition of canni-med therapeutics
byMarc Lakmaaker
 
Aurora investor presentation - january 2018
byAuroraCannabis
 
Zenabis Corporate Presentation
byZenabisIR
 
Management Presentation
bySleepCountry
 
Aurora investor presentation - january 2018
byAuroraCannabis
 
Aurora Investor presentation December 2017
byAuroraCannabis
 
05.08.17 med releaf-en-presentation-amended
bymedreleafinvestor
 

What's hot

PDF
Ipo presentation-april-2017
byrealmatters2016
 
PDF
Sleep country scotia back to school conference 2016
bySleepCountry
 
PPTX
05 08-17-medreleaf-en-presentation-amended-2
bymedreleafinvestor
 
PDF
Hexo and Redecan 2021 investor deck - 7.7.2021
byHexo Corp
 
PDF
May Invest Presentation
bymedreleafinvestor
 
PPTX
Hexo Corp 2021 Q2 investor deck - 5.12.2021
byHexo Corp
 
PDF
Hexo Corp 2020 Q3 investor deck - 8.19.2020
byHexo Corp
 
PDF
Pathway Health Corp November 2021 Company Presentation
byThe Howard Group Inc.
 
PDF
Corporate presentation january 17, 2017 - final
bycorpaveda2015
 
PDF
Relevium Technologies Corporate Presentation
byMomentumPR
 
PDF
Pathway Health Corp September 2021 Presentation
byThe Howard Group Inc.
 
PPTX
Hexo Corp 2021 Q2 investor deck - 5.14.2021
byHexo Corp
 
PDF
Pathway health corporate presentation (june 2021)
byThe Howard Group Inc.
 
PPTX
Hexo 2022 q1 corporate presentation EN
byHexo Corp
 
PDF
Corporate presentation november 2016 final
bycorpaveda2015
 
PDF
Eden 2019 portfolio v32
byDustin Zinger
 
PDF
Harfang Exploration Corporate Presentation - June 2018
byHarfangEx
 
PDF
investor presentation - june 2012
byShona_Energy
 
PPTX
Pathway Health Corporate Presentation - Aug 2021
byThe Howard Group Inc.
 
Ipo presentation-april-2017
byrealmatters2016
 
Sleep country scotia back to school conference 2016
bySleepCountry
 
05 08-17-medreleaf-en-presentation-amended-2
bymedreleafinvestor
 
Hexo and Redecan 2021 investor deck - 7.7.2021
byHexo Corp
 
May Invest Presentation
bymedreleafinvestor
 
Hexo Corp 2021 Q2 investor deck - 5.12.2021
byHexo Corp
 
Hexo Corp 2020 Q3 investor deck - 8.19.2020
byHexo Corp
 
Pathway Health Corp November 2021 Company Presentation
byThe Howard Group Inc.
 
Corporate presentation january 17, 2017 - final
bycorpaveda2015
 
Relevium Technologies Corporate Presentation
byMomentumPR
 
Pathway Health Corp September 2021 Presentation
byThe Howard Group Inc.
 
Hexo Corp 2021 Q2 investor deck - 5.14.2021
byHexo Corp
 
Pathway health corporate presentation (june 2021)
byThe Howard Group Inc.
 
Hexo 2022 q1 corporate presentation EN
byHexo Corp
 
Corporate presentation november 2016 final
bycorpaveda2015
 
Eden 2019 portfolio v32
byDustin Zinger
 
Harfang Exploration Corporate Presentation - June 2018
byHarfangEx
 
investor presentation - june 2012
byShona_Energy
 
Pathway Health Corporate Presentation - Aug 2021
byThe Howard Group Inc.
 

Similar to Aurora investor presentation - April 2018

PDF
April 2018 Aurora Cannabis Investor Presentation
byhughcarter
 
PDF
Pathway Health Corporate Presentation
byThe Howard Group Inc.
 
PDF
Med releaf investor presentation oct 2017 10102017
bymedreleafinvestor
 
PDF
Med releaf investor presentation aug 23 2017 final
bymedreleafinvestor
 
PDF
Med releaf investor presentation nov 2017 112817
bymedreleafinvestor
 
PDF
Med releaf investor presentation aug 2017
bymedreleafinvestor
 
PDF
Med releaf investor presentation dec 2017 12072017
bymedreleafinvestor
 
PDF
Med releaf investor presentation july 19 2017
bymedreleafinvestor
 
PDF
Trulieve Investor Presentation January 2022.pdf
byrmao22394
 
PDF
Introduction to Zenabis
byZenabis
 
PDF
CanniMed Therapeutics Inc. Investor Deck February 2017
byCannimedTherapeutics
 
PDF
Green growth-brands
byHindenburg Research
 
PDF
Hemptown Spring 2019 Investor Presentation
byHemptown USA
 
PDF
IIPR investors company presentation posted
bypatrickmen86
 
PDF
Avicanna Q3 2022 Presentation
byCHF Investor Relations
 
PDF
Avicanna Investor Deck - Q2 2022
byCHF Investor Relations
 
PDF
HEXO Corp 2019 Q2 Investor Relations Deck
byMattWhite142
 
PDF
GrowthStalk Holdings.pdf
byStevenEarley1
 
PDF
Medica Leaf
byRed Rock Entertainment Film Investment
 
PDF
2015 Aphria Medical Marijuana Investor Presentation
byAphriaMMJ
 
April 2018 Aurora Cannabis Investor Presentation
byhughcarter
 
Pathway Health Corporate Presentation
byThe Howard Group Inc.
 
Med releaf investor presentation oct 2017 10102017
bymedreleafinvestor
 
Med releaf investor presentation aug 23 2017 final
bymedreleafinvestor
 
Med releaf investor presentation nov 2017 112817
bymedreleafinvestor
 
Med releaf investor presentation aug 2017
bymedreleafinvestor
 
Med releaf investor presentation dec 2017 12072017
bymedreleafinvestor
 
Med releaf investor presentation july 19 2017
bymedreleafinvestor
 
Trulieve Investor Presentation January 2022.pdf
byrmao22394
 
Introduction to Zenabis
byZenabis
 
CanniMed Therapeutics Inc. Investor Deck February 2017
byCannimedTherapeutics
 
Green growth-brands
byHindenburg Research
 
Hemptown Spring 2019 Investor Presentation
byHemptown USA
 
IIPR investors company presentation posted
bypatrickmen86
 
Avicanna Q3 2022 Presentation
byCHF Investor Relations
 
Avicanna Investor Deck - Q2 2022
byCHF Investor Relations
 
HEXO Corp 2019 Q2 Investor Relations Deck
byMattWhite142
 
GrowthStalk Holdings.pdf
byStevenEarley1
 
Medica Leaf
byRed Rock Entertainment Film Investment
 
2015 Aphria Medical Marijuana Investor Presentation
byAphriaMMJ
 

Aurora investor presentation - April 2018

  • 1.
    A PR IL2018 AGILITY INNOVATION EXECUTION AND EXPANSION Talented, experienced management team driving the sector's fastest growth in customers, revenues and shareholder value
  • 2.
    Forward Looking Statements ThisPresentation (the “Document”) by Aurora Cannabis Inc. (“Aurora” or the “Company”) has been compiled by management of the Company solely for information purposes. The Document has been prepared and dated as of March 31, 2017, and the information contained herein is current as of such date only. The Document under no circumstances is to be construed to be an offering of securities. Neither this Document, nor its delivery to the recipient shall constitute an offer to sell, or the solicitation of an offer to buy the assets described herein. It is provided solely for use by prospective investors in considering their interest. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its business and does not purport to contain all the information that prospective investors may require. Prospective investors should conduct their own investigation and analysis of the Company and its business and the information contained in this Document as well as any additional information provided by the Company. This Document includes forward-looking statements within the meaning of certain securities laws, including the “safe harbour” provisions of the Securities Act (Ontario, Alberta and British Colombia) and other provincial securities law in Canada. These forward- looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward- looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. The Company strongly cautions readers not to place undue reliance on these statements, as a number of important factors, many of which are beyond our control, could cause the Company’s actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to: general economic conditions; pending and proposed legislative or regulatory developments in Canada including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models in Canada; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total patients and customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; structural subordination of common shares; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and future sales of the Company’s securities. The foregoing list of important factors that may affect future results is not exhaustive. When reviewing the Company’s forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by Canadian securities law, the Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by the Company or on the Company’s behalf. Such statements speak only as of the date made. The forward-looking statements contained in this Document should not be relied upon as representing the view of the Company or its management as of any date subsequent to the date of this Document. Neither the Company nor its management is under any obligation, and neither undertakes, to update any of this information at any particular time. Neither the Company nor its management assumes any obligation to update or revise forward-looking statements should circumstances or estimates or opinions changes. None of the Company or its affiliated or related partnerships and corporations or their respective directors, officers, partners, employees, agents or representatives makes any representation or warranty as to the accuracy or completeness of the Document or any statements, estimates or projections, and none will assume any liability for any representations (express or implied) contained in, or for any omissions from, the Document, or for any other written or oral communications transmitted to prospective investors in the course of their evaluation of the Company and its business. An investor will only be entitled to rely on those representations and warranties contained in the definitive agreement or agreements which constitute the financing. This presentation can not be copied, reproduced or distributed in whole or in part to others, at any time, without the prior express written consent of the Company. To the extent that they are included in this document, certain financial metrics can be reported as non-IFRS measures, such as EBITDA (earnings before interest, taxes, depreciation and amortization). For the purposes of this Document, EBITDA is calculated as revenue less cost of sales and operating expenses. The Company believes that these non-IFRS measures are appropriate measures of the operating performance of the Company. The Company’s calculation of these measures may differ from the methodology used by other issuers and, accordingly, may not be comparable to such other issuers. The Company believes that these measures are appropriate measures of the Company’s operating performance because they facilitate an understanding of operating performance without giving effect to certain non-cash and overhead expenses. None of these measures are equivalent to net income or cash flow from operating activities determined in accordance with IFRS. Aurora Cannabis Inc. Management Presentation 2
  • 4.
    Highlights 1. Over 280,000kg per year funded capacity 2. High-technology, ultra-efficient, low cost facilities 3. Strong revenue growth: last reported quarter (Q2 2018): 200% YoY and 41.8% QoQ 4. New production coming online, driving further growth 5. Continuously falling costs of production 6. Corporate expansion: 8 acquisitions and 7 strategic investments in past two years 7. Vertically integrated, horizontally diversified 8. Early mover advantage through rapidly growing international footprint • Own EU’s largest distributor of cannabis • Targeting international markets with nearly 800 million people and strong barriers to entry • Already have presence/sales/agreements in Canada, Germany, Denmark, Italy, Australia, Cayman Islands, South Africa Driven by agility, innovation and execution Aurora Cannabis Inc. Management Presentation 4
  • 5.
    EXCEPTIONALLY WELL POSITIONED TO CAPITALIZEON THE GLOBAL CANNABIS OPPORTUNITY 1VIII Capital, Cannabis Sector, July 2017 CANADA $12 B1 EU $37 B1 ROW $110 B1 PROJECTED MARKET POTENTIAL AGILITY INNOVATION EXECUTION EXPANSION
  • 6.
    Agility • Fastest rampup, execution and sales growth achieved relative to other LP’s • Focused strategy aimed at capitalizing on vertical and horizontal integration opportunities internationally and domestically • High pace of execution ensures early mover advantage and rapid capitalization on opportunities Aurora Cannabis Inc. Management Presentation 6 Source: SEDAR filings Fastest Growing LP’s – Sales License to 650kg/quarter 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 50,000 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18
  • 7.
    Aurora Cannabis Inc.Management Presentation 7 AURORA LARSSEN PROJECTS • World’s premier greenhouse design consultancy AURORA SKY • World’s largest capacity and most technologically advanced cannabis cultivation facility • Optimized for highest yield and lowest cost per gram produced AURORA MOUNTAIN • World’s first fully purpose-built indoor cannabis facility, EU GMP certified CUSTOMER EXPERIENCE • The Aurora Standard: leading edge customer care • Only LP with mobile app for purchasing medical cannabis • Same-day delivery in Calgary, Edmonton and surrounding areas • e-Commerce • Product differentiation RADIENT TECHNOLOGIES – disruptive extraction technology for cannabis oil production NAMASTEMD - exclusive white label use for patient education and registration portal MICRON WASTE TECHNOLOGIES (6.5% interest) – low-cost environmentally friendly treatment of organic waste CANNAROYALTY – acquiring IP for portfolio of novel drug delivery technologies Establishing a world-leading brand, scale and efficiencies Innovation Across all Operational Areas CUSTOMER EXPERIENCE PRODUCTION INNOVAITON- DRIVEN PARTNERSHIPS
  • 8.
    8 GLOBAL EXPANSION VERTICAL INTEGRATION DOMESTICEXPANSION HORIZONTAL DIVERSIFICATION CAPITALIZATION STRATEGY AND EXECUTION 280,000 kg per annum funded capacity Strong balance sheet Direct and indirect presence on 3 continents 200% YoY revenue growth 8 Acquisitions 7 Strategic investments Multiple Strategic partnerships
  • 9.
    Domestic Capacity Expansion 9 FACILITIESMOUNTAIN SKY VIE LACHUTE Footprint (square footage) 55,000 800,000 40,000 48,000 Status Operational since 2015 Licensed in January 2018 Completion by mid- 2018 Completed and Licensed Nov 2017 Completion early calendar 2018 Capacity 4,800 kg/yr 100,000+ kg/yr 4,000+ kg/yr 4,500+ kg/yr Key features First purpose built cannabis facility EU GMP certified Highly automated, technologically advanced cannabis facility for optimized yield and low cost production built to EU GMP standards. Located at Edmonton international airport for superior domestic and global logistics Technologi cally advanced, specialty strains for premium products and medical research Completed to EU GMP standards Nearly completed, state-of-the art facility to be completed to EU GMP standards 1 VIII Capital, Cannabis Sector, July 2017 TGOD Relationship 17.62% ownership interest Supply agreement for up to 23,200 kgpa Status BuIlding Larssen-designed 102,000 kgpa facility in Quebc Completing 14,000 kgpa facility in Ontario Funded Capacity 116,000+ kg/yr Key features Premium organic cannabis producer CANNIMED 97,000 Working on GMP certification Commenced expansion 19,000 kg/yr Current 7,000 kgéyr capacity to be expanded to 19,000 kg per year
  • 10.
    Adding 19,000 kgper annum funded capacity Adding over 20,000 patients Expands international footprint CanniMed Acquisition Aurora Cannabis Inc. Management Presentation 10 To form core of Aurora’s Medical Cannabis Centre of Excellence Adds drug delivery technologies Strong Brands Well Connected Major Expansion Cannabis Oils • Significant sales acceleration since launching oils in 2016 • Phase 1 expansion - $1 billion revenue capacity with 70+% profit margins • 12 million bottles / year @ 165.00 per 60 ml • Completed first oils export to Australia and Cayman Islands • Extraordinary capability and expertise Capsules Production • Expected to accelerate growth in Canada and internationally • For baby boomers looking for a safe, reliable way to manage their chronic pain symptoms and maintain an active lifestyle Topical Cream • Recently launched leading trans-dermal topical cream
  • 11.
    International Expansion Aurora CannabisInc. Management Presentation 11 ~588.8M = combined population Italy Sells cannabis to the Italian government through Pedanios Denmark Owns 51% of Aurora Nordic where Europe’s largest cannabis facility is being built at 1,000,000 sq ft Germany Sells cannabis through Pedanios, leading wholesale importer/exporter/distributer Australia 22.9% interest in Cann Group, first Australian company licenced to cultivate medical cannabis South Africa Definitive agreement to supply cannabis products to Akula Trading 2 Pty Ltd. Cayman Islands First ever sale of commercial cannabis oils Australia First ever shipment of commercial cannabis oils European Union LOI with Creso Pharma Ltd. to market CMED medical cannabis brands Aurora CanniMed Both Aurora & CanniMed • Potentially very large markets • But with strong barriers to entry • Requires EU GMP certification to participate • Aurora is one of few companies with such certification • Accelerating international expansion through CanniMed transaction
  • 12.
    • International medical marketgrowing at a 21% CAGR until 2025 • Near to mid-term expansion through medical-focused opportunities • Multiple GMP-certified facilities to export to international markets Country Population (MM) Medical Cannabis? Name of Regulation Year Voted In Implied Demand (kg per year) Medical Market Sizes If flower Only ($MM) Flower + Extracts ($MM) Active Medical Cannabis Laws Argentina 43.4 ✓ - 2017 316,820 $2,218 $3,564 Austria 8.5 ✓ - 2008 62,050 $434 $698 Australia 23.9 ✓ Narcotics Drug Amendment Bill 2016 174,470 $1,221 $1,963 Canada 35.9 ✓ ACMPR 2001 262,070 $1834 $2,948 Chile 17.9 ✓ Decree 84 2015 130,670 $915 $1470 Columbia 48.2 ✓ - 2015 251,860 $2,463 $3,958 Croatia 4.2 ✓ - 2015 30,660 $215 $345 Czech Republic 10.5 ✓ Amendments 50/2013 Coll. & 221/2013 Coll. 2013 76,650 $537 $862 Germany 80.5 ✓ - 2017 589,110 $4,124 $6,627 Israel 8.1 ✓ - 1992 59,130 $414 $665 Italy 59.8 ✓ - 2007 436,540 $3,056 $4,911 Jamaica 2.8 ✓ Dangerous Drugs (Amendment) Act 2015 2015 20,440 $143 $230 Macedonia 2.1 ✓ - 2016 15,330 $107 $172 Mexico 127 ✓ - 2017 927,100 $6,490 $10,430 Netherlands 16.9 ✓ - 2003 123,370 $864 $1,388 Norway 5.2 ✓ - 2016 37,960 $266 $427 Puerto Rico 3.7 ✓ - 2015 27,010 $189 $304 Romania 19.5 ✓ - 2013 142,350 $996 $1,601 Slovenia 2.1 ✓ - 2014 15,330 $107 $172 Switzerland 8.3 ✓ Federal Act on Narcotics and Psychotropic Substances 2008 60,590 $424 $682 Turkey 78.7 ✓ Legal in 19 provinces 2016 574,510 $4,022 $6,463 Uruguay 3.4 ✓ - 2013 24,820 $174 $279 Subtotal 610.8 4,358,840 $31,212 $50,162 Pending Medical Cannabis Laws or Countries of Interest Belgium 11.3 - - 82,490 $577 $928 Brazil 207.8 - - 1,516,940 $10,619 $17,066 Denmark 5.7 - - 41,610 $291 $468 Finland 5.5 - - 40,150 $281 $452 France 64.4 - - 470,120 $3,291 $5,289 Iceland 0.3 - - 2,190 $15 $25 Ireland 4.7 - - 34,310 $240 $386 New Zealand 4.5 - - 32,850 $230 $370 Poland 38.6 - - 281,780 $1,972 $3,170 Portugal 10.4 - - 75,920 $531 $854 Slovakia 5.4 - - 39,420 $276 $443 South Africa 54.5 - - 397,850 $2,785 $4,476 Spain 46.1 - - 336,530 $2,356 $3,786 United Kingdom 64.7 - - 472,310 $3,306 $5,313 United States 321.8 Legal 29 states and D.C. - 2,349,140 $16,444 $26,428 Subtotal 845.7 6,173,610 $79,154 $127,212 $180B Medical Market Coming Online Over the Next 10-15 Years Eight Capital – 2018 Outlook: legalization will lead to Globalization
  • 13.
    13 Pedanios – Aurora’sGateway to the EU Cannabis Market 82 million population Germany >400 million population EU • Largest medical cannabis distributor in EU (100% owned) • EU GMP certified for import, release and distribution of cannabis • Currently servicing >2,000 pharmacies in Germany (exclusive suppliers of patients) • Access to single largest federally legalized medical cannabis market with population > 82 million • Broad insurance coverage for prescribed medical cannabis • Limited number of EU GMP certified international producers • In phase 2 of tender process for German cultivation license • Won first public tender to supply Italian system Cornerstone acquisition for European expansion strategy
  • 14.
    14 Aurora Nordic –Europe’s Largest Facility at 1,000,000 Square Feet 82 million population Germany Nordic focus wth option to export to wider EU with > 400 M people • Aurora Nordic: 51/49 JV with Alfred Pedersen, one of Europe’s largest greenhouse growers of vegetables (>100,000 kg per day) • Licensed to produce as of Jan 1, 2018 • To construct ALPS-designed high- technology facility • At 1,000,000 sqft, this will be largest cannabis facility in Europe • Focused on Nordic countries and export to rest of EU through Pedanios • Built to EU GMP standards for export • Retrofitting existing greenhouse for 8,000 kgpa capacity while main facility is being constructed JV Partner Recognized as one of Denmark’s leading entrepreneurs
  • 15.
    Aurora – IndustryLeading International Strategic Partnerships CanniMed – Strong International Presence With Meaningful Distribution Partners • Over the last two years, Aurora has completed 15 acquisitions and strategic investments, including: o Pedanios – EU`s largest distributor of cannabis, based in Germany – EU GMP certified o LIQ – Strategic investment in Western Canada’s largest liquor retail chain. LIQ to convert existing retail outlets and establish new ones for the sale of cannabis for the adult consumer use market o Radient Technologies – Partnership for the high-throughput extraction of cannabinoids Vertical Integration – Horizontal Diversification 15 Akula Trading 2 Pty Ltd. • CanniMed has built strong partnerships that position it well for future growth: o Avaria – CanniMed entered into an agreement with Avaria Health & Beauty Corp for the distribution of topical medical cannabis products, product development, and clinical research o PharmaChoice – Entered into Canada’s first exclusive pharmacy distribution agreement for medical cannabis o Canadian Cancer Survivor Network – Partnered with Canadian Cancer Survivor Network for medical cannabis education
  • 16.
    Adult Consumer UseMarket – LIQ Partnership • Acquired 19.9% of issued and outstanding shares in Liquor Stores N.A. (“LIQ”), with option to increase ownership to 40% • LIQ will use proceeds to convert existing stores, as well as build new stores, into cannabis retail outlets • LIQ has strong presence in Western Canada with over 200 liquor stores • One of the dominant retail brands in Western Canada • Ensures LIQ and Aurora will be ready on Day One of the commencement of cannabis sales for the adult consumer market, once legalized • Leveraging LIQs deep expertise, capabilities and capacity in operating a network of retail outlets • Aurora to contribute branding, product knowledge and understanding of the cannabis culture and markets Aurora Cannabis Inc. Management Presentation 16
  • 17.
    BC Northern Lights– Supporting the Home Grow Market • The gold-standard in indoor grow boxes • Only purpose-built growing appliance on the market • Odor-free operation, ideal for multi-unit dwellings • Lockable doors • Only growing appliance that offers CSA/UL safety approval • Produced using premium materials and components only • Medical grade powder coated aluminum to avoid any mold or mildew issues • 20-year track record • Exceptional customer care • Customized nutrient management plans • Unlimited toll-free technical support • Live streaming “Growinars” • BCNL customers can speak to experienced growers and technicians seven days a week Aurora Cannabis Inc. Management Presentation 17
  • 18.
  • 19.
    Aurora Cannabis Inc.Management Presentation 19 Sequential Growth (%) 200% YoY growth for Q2 2018 457.1% 151.7% 26.5% 33.2% 14.7% 39.0% Strong Revenue Growth Revenue ($M) $0.00 $2.00 $4.00 $6.00 $8.00 $10.00 $12.00 $14.00 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 41.8%
  • 20.
    Rapid Development Relativeto Sector Aurora Cannabis Inc. Management Presentation 20 0 5 10 15 20 25 Dec-14 Mar-15 Jun-15 Sep-15 Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Mar-17 Jun-17 Sep-17 Dec-17 LPs Revenue Development ACB WEED APH LEAF CMED ACB+CMED Notes to chart: LPs have different reporting schedules. For comparison reasons, revenues have been assigned to the corresponding Aurora quarter.
  • 21.
    Strong Execution DrivesFastest Revenue Development Aurora Cannabis Inc. Management Presentation 21 0 2 4 6 8 10 12 14 1Q 2Q 3Q 4Q 5Q 6Q 7Q 8Q ACB WEED APH Revenue development first 8 quarters from commencement of sales 0 5 10 15 20 25 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 ACB WEED APH LEAF CMED ACB+CMED Revenue development since ACB commenced sales
  • 22.
    Aurora Cannabis Inc.Management Presentation 22 Continuously Improving Metrics Q2 2018 Q1 2018 Q4 2017 Q3 2017 Q2 2017 # # # # # Active registered patients (1) 23,000 19,280 16,400 13,110 12,200 Grams sold 1,161,809 889,965 755,059 653,008 538,045 Grams produced (2) 1,204,259 1,009,585 1,164,683 846,849 670,322 (In CDN $000’s unless otherwise noted) $ $ $ $ $ Average net selling price per gram 8.36 8.22 7.45 6.64 5.96 Cash cost of sales per gram 1.74 1.92 2.09 2.31 2.56 Cash cost to produce per gram 1.41 1.73 1.91 1.91 2.13 Cash and cash equivalents 350,841 127,915 159,796 111,116 55,846
  • 23.
    Aurora Cannabis Inc.Management Presentation 23 Company invested in Shares bought Average price Current Value RoI #(million) $ (million) $ (million) % Cann Group 28.8 0.84 82.9 Radient Technologies 23.2 0.57 38.5 Hempco Food and Fiber 10.6 0.31 11.4 Micron Waste Technologies 4.4 0.34 2.1 TOTAL 135 >200% Value Creation Through Strategic Investments Exceptional investment track record Also completed $55 million investment into The Green Organic Dutchman (private)
  • 24.
    HIGHLIGHTS 24 Fastest patient signup rate in industry Scale to service both rapidly growing medical market and seize legalization opportunity Extremely well capitalized to pursue global expansion opportunity • Upon completion, six facilities • > 280,000 kg per annum funded production capacity • Technologically most advanced facilities => ultra low cost of production • CanniMed acquisition • Pedanios - Germany & EU • Cann Group – Australia • Aurora Nordic - Denmark SCALE • Disruptive extraction technology • First mobile app for ordering medical cannabis • Customer care: same day delivery in two metropolitan areas INNOVATION • Technology-driven cultivation philosophy to produce high-quality cannabis at ultra low cost • Diversifying product offering into adjacent markets, accessing additional revenue streams DIFFERENTIATION/DIVERSIFICAITON INTERNATIONAL EXPANSION
  • 25.
  • 26.
    Experienced Leadership Team AuroraCannabis Inc. Management Presentation 26 Terry Booth CEO CEO of 6 successful companies 25 years experience in highly regulated industries Cam Battley Chief Corporate Officer Deep experience in pharma and cannabis sectors Board member Cannabis Canada Steve Dobler President Successful entrepreneur, member of many public companies’ board of directors. Responsible for raising substantial funds for Aurora Glen Ibbott CFO Strong senior financial executive with deep life sciences sector experience Neil Belot Chief Global Business Development Officer Former executive director of Cannabis Canada - Canada's trade association for Licensed Producers Allan Cleiren COO Experienced operational executive with nearly three decades leadership experience at private and public companies Darryl Vleeming Chief Information Officer over 20 years of experience in Senior IT leadership, project delivery, and IT strategic planning at publicly traded international corporations, with a specific focus on driving business value.
  • 27.
    Board of Directors AuroraCannabis Inc. Management Presentation 27 Steve Dobler President, Aurora Successful entrepreneur, member of many public companies’ board of directors. Responsible for raising substantial funds for Aurora Adam Szweras Partner, Fogler, Rubinoff LLP Experienced securities lawyer. Founder of a US developer of marijuana and hemp oil, and edible products. Michael Singer Chairman CFO, Clementia Pharmaceuticals Former CFO, Bedrocan Cannabis Corp. Terry Booth CEO, Aurora CEO of 6 successful companies 25 years experience in highly regulated industries Dr. Jason Dyck Professor, Department of Pediatrics and Director of Cardiovascular Research Centre, University of Alberta Diane Jang A business consultant, specializing in strategic planning for sustainable success, growth and profitability, with over 27 years of business experience in the Consumer Packaged Goods industry
  • 28.
    28 AGILITY INNOVATION EXECUTIONEXPANSION Talented, experienced management team driving the sector's fastest growth in customers, revenues and shareholder value
  • 29.
    Aurora Information Established 2013 ~750 Employees 6Directors Head Office 1500 -1199 West Hastings St. Vancouver, BC V6E 3T5 TSX: ACB OTCQX: ACBFF Aurora Cannabis Inc. Management Presentation 29
  • 30.
    Capital Summary Market Cap- Basic $4.5 Billion Share Price - April 3, 2018 $8.07 Aurora Cannabis Inc. Management Presentation 30Strong balance sheet to fuel further growth April 3, 2018 TSX listed, ticker symbol ACB Securities Issued & Outstanding Shares* 561,061,244 Options 25,087,884 Warrants 8,615,348 Convertible debentures shares reserved for issuance 17,976,203 Fully Diluted 614,890,679
  • 31.
    Contact Information Cam Battley ChiefCorporate Officer +1 (905) 878-5525 cam@auroramj.com 31 Marc Lakmaaker, Director IR & Corporate Development +1 (647) 269-5523 Marc.lakmaaker@auroramj.com